BioCryst Completes $65.3 Million Private Placement Financing

BIRMINGHAM, Ala., Aug. 9 /PRNewswire-FirstCall/ — BioCryst Pharmaceuticals, Inc. today announced that it has completed a $65.3 million private placement of approximately 8.3 million shares of its common stock and warrants to purchase an additional approximately 3.2 million shares of common stock. The purchase price for the shares was $7.80 per share, the closing Nasdaq composite bid price for the company’s common stock immediately preceding execution of the definitive agreement for the transaction and the exercise price for the warrants is $10.25. Investors in the financing paid an additional purchase price equal to $0.125 for each share underlying the warrants.

Participants in the transaction included funds managed by Baker Brothers Investments, Kleiner Perkins Caufield & Byers, EHS Holdings, OrbiMed Advisors, Texas Pacific Group Ventures, and Stephens Investment Management.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: